



Date: 03rd February, 2026

To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex Bandra (East) <u>Mumbai – 400 051</u> Stock Code : INDOCO	To The Listing Department Bombay Stock Exchange Limited Floor 25, P. J. Towers, Dalal Street, <u>Mumbai – 400 001</u> Stock Code : 532612
--	---

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on 03rd February, 2026

Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 03rd February, 2026 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine Months Ended 31st December, 2025 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results.

Please find enclosed copies of the following:

1. Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine Months Ended 31st December, 2025 as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. Limited Review Report with unmodified opinion issued by our Statutory Auditors M/s. Gokhale & Sathe, Chartered Accountants.
3. Press Release.

The Board Meeting commenced today at 11:05 a.m. and concluded at 11:50 a.m. You are requested to kindly take the same on record.

Thanking you,
Yours faithfully,
For Indoco Remedies Limited

RAMANATHA
N HARIHARAN
Digitally signed by
RAMANATHAN HARIHARAN
Date: 2026.02.03 11:51:57
+05'30'



Ramanathan Hariharan
Company Secretary & Head- Legal

INDOCO REMEDIES LIMITED

Indoco House, 166, C.S.T. Road, Kalina, Santacruz (E), Mumbai 400098, India.
Tel. No.: +91 22 6287 1000 / 6879 1250 ■ CIN: L85190MH1947PLC005913

www.indoco.com

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2025

(Rs. In Lakhs)

S.No.	Particulars	Quarter ended 31.12.2025 (Unaudited)	Quarter ended 30.09.2025 (Unaudited)	Quarter ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
1	Income from Operations						
	(a) Revenue from Operations	38,957	42,930	36,491	1,20,448	1,15,371	1,49,478
	(b) Other Operating Income	1,094	1,282	807	3,246	1,723	2,341
	Total Income from Operations (Net) (a+b)	40,051	44,212	37,298	1,23,694	1,17,094	1,51,819
2	Other Income	717	654	426	1,929	1,198	1,848
3	Total Income (1+2)	40,768	44,866	37,724	1,25,623	1,18,292	1,53,667
4	Expenses						
	(a) Cost of materials consumed	8,119	8,602	9,154	25,498	26,257	33,479
	(b) Purchases of stock-in-trade	3,299	3,882	3,494	11,104	11,031	14,093
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(159)	404	(2,226)	(338)	(1,906)	(3,204)
	(d) Employee Benefits expense	9,881	9,534	9,072	29,265	26,880	36,874
	(e) Research & Development Expense	1,831	2,181	1,866	6,178	5,862	7,601
	(f) Other Expenses	14,490	14,270	13,924	42,575	36,512	50,172
	(g) Finance Costs	2,015	2,201	1,400	6,577	4,065	5,663
	(h) Depreciation and Amortization expense	2,736	2,763	2,475	8,019	7,337	9,825
	Total Expenses	42,212	43,837	39,159	1,28,878	1,16,038	1,54,503
5	Profit / (Loss) Before Exceptional Items and Tax (3-4)	(1,444)	1,029	(1,435)	(3,255)	2,254	(836)
6	Exceptional Items (*)	(601)	(53)	99	(654)	99	99
7	Profit Before Tax (5+6)	(2,045)	976	(1,336)	(3,909)	2,353	(737)
8	Tax Expenses - Current	-	-	(504)	-	293	-
	- Deferred	(45)	(529)	191	(608)	309	136
	- MAT Credit Adjustments	-	-	-	-	-	-
	Total Tax Expenses	(45)	(529)	(313)	(608)	602	136
9	Profit for the period (7-8)	(2,000)	1,505	(1,023)	(3,301)	1,751	(873)
10	Other Comprehensive Income						
a	i) Items that will not be reclassified to profit and loss	(75)	(75)	(30)	(225)	(90)	(600)
	ii) Income tax on relating to this item	19	19	8	57	23	151
b	i) Items that may be reclassified to profit or loss	54	152	-	335	-	-
	ii) Income tax on relating to this item	(13)	(39)	-	(84)	-	-
	Total Other Comprehensive Income	(15)	57	(22)	83	(67)	(449)
11	Total Comprehensive income for the year (9+10)	(2,015)	1,562	(1,045)	(3,218)	1,684	(1,322)
12	Paid up Equity Share Capital (Face value Rs. 2/- each)	1,845	1,845	1,844	1,845	1,844	1,845
13	Other Equity						
14	Earnings per share (of Rs. 2/- each)						
	(a) Basic- in Rs.	(2.17)	1.63	(1.11)	(3.58)	1.90	(0.95)
	(b) Diluted- in Rs.	(2.17)	1.63	(1.11)	(3.58)	1.90	(0.95)

Notes:

- The unaudited Standalone Results for the Quarter and Nine Months ended 31st December, 2025 have been reviewed by the Audit committee and approved by the Board of Director of the Company at its meeting held on 03rd February, 2026. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Standalone Financial Results.
- The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.
- The company has only one primary reportable segment of activity, namely, Pharmaceuticals.
- Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:

(Rs. In Lakhs)

Net Sales and Income from Operations	Quarter ended 31.12.2025 (Unaudited)	Quarter ended 30.09.2025 (Unaudited)	Quarter ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
India	23,060	24,735	23,935	70,050	69,959	91,598
Outside India	15,897	18,195	12,556	50,398	45,412	57,880
Total	38,957	42,930	36,491	1,20,448	1,15,371	1,49,478

5 The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 31st December, 2025.

6 (*) Exceptional items includes : (a) Consideration received Rs. 253 lakhs for grant to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company, (b) Loss amounting to Rs. 213 lakhs on sale and leaseback of its Non current Assets, and, (c) Impact of past period employee benefit liability amounting to Rs. 694 lakhs due to implementation of the New Labour Codes.

7 Effective 21st November, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by Rs. 694 lakhs primarily arising due to change in definition of "wages" for employees and contract labours. Considering the materiality and nonrecurring nature of this impact, the Company has presented such incremental impact under 'Exceptional Item' in the standalone financial results for the quarter and nine months ended 31st December, 2025. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards.

By Order of the Board
 For Indoco Remedies Ltd

Aditi Panandikar
 Managing Director

Place : Mumbai
 Date : February 03, 2026





Independent Auditors' Limited Review Report on quarterly and year-to-date unaudited standalone financial results of Indoco Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors,
Indoco Remedies Limited

- 1 We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of Indoco Remedies Limited ('the Company') for the quarter ended **31st December 2025** and year to date results for the period 1 April 2025 to 31 December 2025, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015 as amended.
- 2 This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3 We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures.



A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

- 4 Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

5 **Emphasis of Matter**

We draw attention to Note on Non-current Financial Investment in Standalone financial statements-

A) FPP Holding LLC

The Company incurred a net profit of Rs 224.19 Lakhs during the quarter ended 31st December 2025 and a cumulative net loss of Rs. 1,002.63 Lakhs for the period 1st April 2025 to 31st December 2025. As at that date, the Company has a negative networth of Rs 3,427.78 Lakhs.

B) Warren Remedies Private Limited

The Company incurred a net loss of Rs 843.00 Lakhs during the quarter ended 31st December 2025 and a cumulative loss of Rs. 2,835.43 Lakhs for the period 1st April 2025 to 31st December 2025. As at that date, the Company has a negative networth of Rs 5,900.03 Lakhs.



These conditions indicate the existence of a material uncertainty that may cast significant doubt on the ability of the respective companies to continue as going concerns. In accordance with the requirements of Ind AS 36, Impairment of Assets, the Group has carried out impairment testing of the carrying amounts of its investments in these subsidiaries, given the erosion of their net worth. Based on the impairment assessment performed by management, which included review of long-term business plans, cash flow forecasts, and other relevant assumptions, the recoverable amounts of these investments were estimated to exceed their respective carrying values. Accordingly, no impairment provision has been considered necessary by the management at this stage.

Our opinion is not modified in respect of this matter.

For Gokhale & Sathe,
Chartered Accountants
Firm Registration No.: 103264W



Atul Kale
Partner
Membership Number -109947
UDIN: 26109947WSULDR4202
Place: Mumbai
Date: 03rd February 2026

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2025

(Rs. In Lakhs)

S.No.	Particulars	Quarter ended 31.12.2025 (Unaudited)	Quarter ended 30.09.2025 (Unaudited)	Quarter ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
1	Income from Operations						
	(a) Revenue from Operations	43,434	47,183	40,245	1,33,704	1,25,740	1,64,129
	(b) Other Operating Income	1,102	1,284	810	3,267	1,731	2,363
	Total Income from Operations (Net) (a+b)	44,536	48,467	41,055	1,36,971	1,27,471	1,66,492
2	Other Income	98	76	85	337	343	545
3	Total Income (1+2)	44,634	48,543	41,140	1,37,308	1,27,814	1,67,037
4	Expenses						
	(a) Cost of materials consumed	9,789	11,299	10,991	31,641	31,041	39,627
	(b) Purchases of stock-in-trade	3,299	3,882	3,493	11,104	11,031	14,093
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,046)	(647)	(3,092)	(2,672)	(2,851)	(3,902)
	(d) Employee Benefits expense	10,603	10,323	9,755	31,628	28,769	39,405
	(e) Research & Development Expense	1,831	2,181	1,866	6,178	5,862	7,601
	(f) Other Expenses	16,909	17,124	16,839	49,882	43,615	59,742
	(g) Finance Costs	2,564	2,456	1,611	7,632	4,825	6,623
	(h) Depreciation and Amortization expense	3,201	3,225	2,872	9,396	8,506	11,384
	Total Expenses	47,150	49,843	44,335	1,44,789	1,30,798	1,74,573
5	Profit Before Exceptional Items and Tax (3-4)	(2,516)	(1,300)	(3,195)	(7,481)	(2,984)	(7,536)
6	Exceptional Items (*)	(615)	(53)	99	(668)	99	99
7	Profit / (Loss) Before Tax (5+6)	(3,131)	(1,353)	(3,096)	(8,149)	(2,885)	(7,437)
8	Tax Expenses - Current	1	5	(500)	6	317	47
	- Deferred	(187)	(437)	244	(655)	459	311
	- MAT Credit Adjustments	-	-	-	-	-	-
	Total Tax Expenses	(186)	(432)	(256)	(649)	776	358
9	Profit for the period (7-8)	(2,945)	(921)	(2,840)	(7,500)	(3,661)	(7,795)
10	Other Comprehensive Income						
a	i) Items that will not be reclassified to profit and loss	(77)	(77)	(30)	(230)	(90)	(604)
	ii) Income tax on relating to this item	19	19	7	57	23	152
b	i) Items that may be reclassified to profit or loss	(48)	365	12	404	(70)	33
	ii) Income tax on relating to this item	(20)	(49)	(2)	(114)	17	6
	Total Other Comprehensive Income	(126)	258	(13)	117	(120)	(413)
11	Total Comprehensive Income for the year (9+10)	(3,071)	(663)	(2,853)	(7,383)	(3,781)	(8,208)
	Profit attributable to :						
	Equity Shareholders of the Company	(2,979)	(793)	(2,639)	(7,350)	(3,335)	(7,374)
	Non-Controlling Interest - Profit / (Loss)	34	(128)	(201)	(150)	(326)	(421)
	(2,945)	(921)	(2,840)	(7,500)	(3,661)	(7,795)	
	Other comprehensive income is attributable to:						
	Equity Shareholders of the Company	(126)	258	(13)	117	(120)	(413)
	Non-Controlling Interest	-	-	-	-	-	-
	Total comprehensive income is attributable to:						
	Equity Shareholders of the Company	(126)	258	(13)	117	(120)	(413)
	Non-Controlling Interest - Profit / (Loss)	(3,105)	(535)	(2,652)	(7,233)	(3,455)	(7,787)
		34	(128)	(201)	(150)	(326)	(421)
	(3,071)	(663)	(2,853)	(7,383)	(3,781)	(8,208)	
12	Paid up Equity Share Capital (Face value Rs. 2/- each)	1845	1,845	1844	1,845	1,844	1,845
13	Other Equity						1,00,355
14	Earnings per share (of Rs. 2/- each)						
	(a) Basic- in Rs.	(3.20)	(1.00)	(3.08)	(8.14)	(3.97)	(8.46)
	(b) Diluted- in Rs.	(3.19)	(1.00)	(3.08)	(8.13)	(3.97)	(8.45)

Notes :

- The unaudited Consolidated Results for the Quarter and Nine Months ended 31st December, 2025 have been reviewed by the Audit committee and approved by the Board of Director of the Company at its meeting held on 03rd February, 2026. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Consolidated Financial Results.
- The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.
- The company has only one primary reportable segment of activity, namely, Pharmaceuticals.
- Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:

Net Sales and Income from Operations	Quarter ended 31.12.2025 (Unaudited)	Quarter ended 30.09.2025 (Unaudited)	Quarter ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
India	29,544	30,370	28,162	87,698	82,853	1,09,039
Outside India	13,890	16,813	12,083	46,006	42,887	55,090
Total	43,434	47,183	40,245	1,33,704	1,25,740	1,64,129

- The Consolidated Financial Results includes the Results of the following Companies

Name of the Company	% of Shareholding	Consolidated as
Xtend Industrial Designers & Engineers Pvt. Ltd.	100	Subsidiary
Indoco Remedies Czech S R O	100	Subsidiary
Indoco Remedies UK Ltd.	100	Subsidiary
Warren Remedies Private Limited	100	Subsidiary
PPP Holding Company, LLC	85	Subsidiary

- The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 31st December, 2025.
- (*) Exceptional items includes : (a) Consideration received Rs. 253 lakhs for grant to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company, (b) Loss amounting to Rs. 213 lakhs on sale and leaseback of its Non current Assets, and, (c) Impact of past period employee benefit liability amounting to Rs. 708 lakhs due to implementation of the New Labour Codes.
- Effective 21st November, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Group has assessed the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by Rs. 708 lakhs primarily arising due to change in definition of "wages" for employees and contract labours. Considering the materiality and nonrecurring nature of this impact, the Group has presented such incremental impact under "Exceptional Item" in the consolidated financial results for the quarter and nine months ended 31st December, 2025. The Group continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards.





Independent Auditors' Limited Review Report on quarterly and year-to-date unaudited consolidated financial results of Indoco Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors,
Indoco Remedies Limited

- 1 We have reviewed the accompanying statement of unaudited consolidated financial results of Indoco Remedies Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') for the quarter ended 31 December 2025 and year to date results for the period 1 April 2025 to 31 December 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
- 3 We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

- 4 This statement includes the results of the following entities:
 - a) Xtend Industrial Designers and Engineers Private Limited
 - b) Indoco Remedies Czech sro
 - c) Indoco Remedies UK Limited
 - d) Warren Remedies Private Limited
 - e) FPP Holding Company, LLC (wef 5 June 2023)
 - f) Florida Pharmaceuticals Products LLC (wholly owned subsidiary of FPP Holding Company, LLC), wef 5 June 2023
- 5 Based on our review and procedures performed as stated in paragraph 3 above and based on consideration of the review reports of the auditors referred in paragraph no 6 and 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6 We did not review the interim financial statements of one subsidiary included in the statement of unaudited consolidated financial results, whose unaudited financial statements reflect total revenues of Rs. 20.30 Lakhs, and Rs. 146.04 Lakhs and total net profit after tax of Rs. 4.28 Lakhs and Rs. 19.54 Lakhs for the quarter ended 31 December 2025 and for the period 1 April 2025 to 31 December 2025, respectively as considered in the Statement. This financial information has been reviewed by other auditors whose reports has been furnished to us by the management and our conclusion on the Statements, in so far as it relates to the



amounts and disclosures included in respect of these subsidiary is based solely on the report of other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of such matter.

- 7 The unaudited consolidated financial results also include the financial information of 3 foreign subsidiaries and 1 step down wholly owned subsidiary, which have not been reviewed, whose financial information reflects total revenues of Rs. 3,111.33 Lakhs and Rs. 8,179.73 Lakhs and total net profit after tax of Rs 223.63 Lakhs and total net loss after tax of Rs. 1,003.19 Lakhs for the quarter ended 31 December 2025 and for the period 1 April 2025 to 31 December 2025, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information/financial results are not material to the Group.

8 **Emphasis of Matter**

We draw attention to Note on Non-current Financial Investment in Standalone financial statements-

A) FPP Holding LLC

The Company incurred a net profit of Rs 224.19 Lakhs during the quarter ended 31st December 2025 and a cumulative net loss of Rs. 1,002.63 Lakhs for the period 1st April 2025 to 31st December 2025. As at that date, the Company has a negative networth of Rs 3,427.78 Lakhs.

B) Warren Remedies Private Limited

The Company incurred a net loss of Rs 843.00 Lakhs during the quarter ended 31st December 2025 and a cumulative loss of Rs. 2,835.43 Lakhs for the period 1st April 2025 to 31st December 2025. As at that date, the Company has a negative networth of Rs 5,900.03 Lakhs.



gokhale & sathe (regd.)
chartered accountants
304/308/309, Udyog Mandir No. 1,
7-C, Bhagoji Keer Marg,
Mahim, Mumbai 400 016

These conditions indicate the existence of a material uncertainty that may cast significant doubt on the ability of the respective companies to continue as going concerns. In accordance with the requirements of Ind AS 36, Impairment of Assets, the Group has carried out impairment testing of the carrying amounts of its investments in these subsidiaries, given the erosion of their net worth. Based on the impairment assessment performed by management, which included review of long-term business plans, cash flow forecasts, and other relevant assumptions, the recoverable amounts of these investments were estimated to exceed their respective carrying values. Accordingly, no impairment provision has been considered necessary by the management at this stage.

Our conclusion on the Statement is not modified in respect of the above matter.

For Gokhale & Sathe,
Chartered Accountants
Firm Registration No.: 103264W



Atul Kale
Partner
Membership Number -109947
UDIN: **26109947TKYSCM9041**
Place: Mumbai
Date: 03rd February 2026



PRESS RELEASE

Indoco Q3 revenues grew 7 % YoY

Mumbai, February 3, 2026 : During the third quarter of FY 2025-26, revenues of Indoco Remedies are at ₹ 3,896 mn, as against ₹ 3,649 mn, in the same quarter last year, registering a 7 % revenue growth. EBIDTA for the quarter is at ₹ 259 mn, compared to ₹ 201 mn in the same quarter last year, registering a 29 % growth.

Commenting on the results, Ms. Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, "The revenue growth in this quarter is mainly due to the Export Formulations business and API business."

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US\$ 180 million with a human capital of over 6000 employees, including over 300 skilled scientists and field staff who are the strength of the organization.

The Company has 10 manufacturing facilities, 6 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,40,000 doctors belonging to various specialties. Indoco has 10 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, OxiPod, Cital, Senoform, Sensodent-KF, Aloja, Glychek, Kidodent, Subitral, Rexidin, MCBM 69, Methycal, Dropizin, Noxa, Homide, Cal-Aid, Ninaf, Cital-Uti, Otorex, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:



Mr. Anuj Sonpal
Valorem Advisors
Tel: +91-22-4903-9500
Email:
indoco@valoremadvisors.com/corpcom@indoco.com